Research Studies:
KALETRA
MONOTHERAPY
Kaletra is an anti-HIV drug belonging to the group known as protease inhibitors. Protease inhibitors prevent cells infected by HIV from producing new virus. Kaletra is a safe, potent and well-tolerated drug, which was approved by the Food and Drug Administration in 2000 and has been widely used in the treatment of HIV infection. It is unique among protease inhibitors because it contains two protease inhibitors, lopinavir (the active drug) and ritonavir, which boosts the level of lopinavir in the blood. Another unique feature is that to date no resistance to Kaletra has been described among people taking Kaletra as their first protease inhibitor.
Purpose: |
The purpose of this study is to determine whether taking Kaletra as a single anti-HIV drug will provide a sustained and powerful anti-HIV regimen, enhancing your quality of life and with few side effects
|
Eligibility
Criteria: |
You are eligible to take part in this study if:
- You have not taken any anti-HIV medications previously, OR
- You have taken anti-HIV medications previously but have never taken a protease inhibitor and you are experiencing treatment failure on your current regimen.
Other Eligibility Criteria
- Any CD4 cell count
- Viral load > 1,000 copies/mL on last two consecutive estimates, not less then one month apart, and the latest of these not more than two months prior to entry.
- Subjects with active or past Hepatitis C infection may enroll.
|
Study
Requirements: |
The duration of this study is 48 weeks and you will be asked to come in for approximately 15 study visits.
|
Benefits: |
You will receive $25 for each visit to cover study-related expenses, such as meals, transportation, and parking, for a total of $400 for the study if you attend all visits.
|
Study
Personnel: |
| Christine A. Wanke,
MD |
Principle Investigator |
|
Contact: |
Privacy and confidentiality are strictly maintained.
TOP
|
|
